James Orsini

463 total citations
15 papers, 225 citations indexed

About

James Orsini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, James Orsini has authored 15 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in James Orsini's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (5 papers). James Orsini is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Treatment and Pharmacology (5 papers). James Orsini collaborates with scholars based in United States, Japan and Canada. James Orsini's co-authors include Vera Hirsh, Mark A. Socinski, Jeremy K. Hon, Ray D. Page, Isamu Okamoto, Markus F. Renschler, Shaker R. Dakhil, Corey J. Langer, Nobuyuki Yamamoto and Hui Zhang and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

James Orsini

14 papers receiving 223 citations

Peers

Countries citing papers authored by James Orsini

Since Specialization

Citations

This map shows the geographic impact of James Orsini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Orsini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Orsini more than expected).

Fields of papers citing papers by James Orsini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Orsini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Orsini. The network helps show where James Orsini may publish in the future.

Co-authorship network of co-authors of James Orsini

This figure shows the co-authorship network connecting the top 25 collaborators of James Orsini. A scholar is included among the top collaborators of James Orsini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Orsini. James Orsini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK) 2025 ·JCO Precision Oncology ·Jens Samol, (unknown), Jonathan Poh, Min-Han Tan, (unknown), Jennifer Carney, James Orsini, Katherine A. Scilla, (unknown), Tan Min Chin, Chee‐Keong Toh, Boon Cher Goh, Gilberto Lopes	4
2	Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials. 2024 ·Journal of Clinical Oncology ·Ajeet Gajra, (unknown), Sibel Blau, Julio A. Peguero, Mahran Shoukier, (unknown), (unknown), (unknown), (unknown), (unknown), Stephan DiSean Kendall, James Orsini, Sunil Babu, Jessica A. Hellyer, (unknown), (unknown), (unknown), (unknown), (unknown), Matthew M. Cooney	1
3	Leveraging machine learning technology to efficiently identify and match patients for precision oncology clinical trials. 2021 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), A. N. Grigorenko, Andrew Stewart, (unknown), (unknown), (unknown), William Bennett, (unknown), Sibel Blau, Abhinav Chandra, Petros Nikolinakos, James Orsini, Julio A. Peguero, Kimberly Blackwell, Matthew M. Cooney	1
4	Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC) 2020 ·Cancer Epidemiology Biomarkers & Prevention ·Benjamin Musher, Joshua Melson, (unknown), David W. Chan, (unknown), Iftekhar Khan, Samith T. Kochuparambil, Susan E. Lyons, James Orsini, Susanne K. Pedersen, Bruce W. Robb, Joel Saltzman, (unknown), (unknown), Melissa Tuck, Lawrence C. LaPointe, Graeme P. Young	25
5	Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer. 2020 ·Journal of Clinical Oncology ·R. Brian Mitchell, Patricia Rich, Paul R. Walker, Eric Schaefer, Jiahuai Tan, (unknown), J W Dubay, (unknown), (unknown), (unknown), Ray D. Page, (unknown), (unknown), (unknown), (unknown), Edgardo S. Santos, James Orsini, (unknown), Wallace Akerley, (unknown)	1
6	Real-world Performance of Blood-Based Proteomic Profiling in Frontline Immunotherapy Treatment in Advanced stage NSCLC 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Patricia Rich, Joanna Roder, J W Dubay, (unknown), (unknown), James Orsini, Edgardo S. Santos, Morton Coleman, (unknown), Wallace Akerley, Robert D. Siegel, (unknown), Paul R. Walker	3
7	Clinical concordance study of a 17-gene liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). 2018 ·Journal of Clinical Oncology ·Lee S. Schwartzberg, Emilio Esteban, Dolores Isla, Michaela L. Tsai, Fabrice Barlési, Frédérique Penault‐Llorca, Hidehito Horinouchi, William Irvin, (unknown), James Orsini, Amparo Sánchez-Gastaldo, John A. Keech, (unknown), John Crown, Nashat Gabrail, (unknown), Anna Bergamaschi, Margarita Lopatin, Christer Svedman, David Chan	1
8	PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Paul R. Walker, Eric Schaefer, Patricia Rich, J W Dubay, (unknown), (unknown), (unknown), James Orsini, Edgardo S. Santos, (unknown), C. Jordan, Ray D. Page, Antoine Arnaud, (unknown)	0
9	Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer 2013 ·Annals of Oncology ·Mark A. Socinski, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, Nobuyuki Yamamoto, (unknown), Markus F. Renschler	57
10	Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Vera Hirsh, Isamu Okamoto, Jeremy K. Hon, Ray D. Page, James Orsini, Hiroshi Sakai, Hui Zhang, Markus F. Renschler, Mark A. Socinski	30
11	Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer 2012 ·Annals of Oncology ·Mark A. Socinski, Corey J. Langer, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, (unknown), Markus F. Renschler	92
12	Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). 2012 ·Journal of Clinical Oncology ·Markus F. Renschler, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, Hui Zhang, Mark A. Socinski	4
13	Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). 2012 ·Journal of Clinical Oncology ·Mark A. Socinski, Corey J. Langer, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, Hui Zhang, Markus F. Renschler	1
14	Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms. 2012 ·Journal of Clinical Oncology ·Vera Hirsh, Isamu Okamoto, Jeremy K. Hon, Shaker R. Dakhil, Ray D. Page, James Orsini, Hui Zhang, Markus F. Renschler, Mark A. Socinski	1
15	Cystosarcoma phylloides: A case presentation 1981 ·Medical and Pediatric Oncology ·James Orsini, Marjorie Perloff, B Rybak	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact